{"id":51886,"date":"2022-12-12T23:02:29","date_gmt":"2022-12-12T22:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/"},"modified":"2022-12-12T23:02:29","modified_gmt":"2022-12-12T22:02:29","slug":"quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/","title":{"rendered":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles"},"content":{"rendered":"
\n

\nLead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman
\n
<\/i>Douglas Bryant to continue as Chief Executive Officer and Director; Assumes role as President<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (Nasdaq: QDEL) <\/b>(\u201cQuidelOrtho\u201d or the \u201cCompany\u201d), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its Board of Directors (the \u201cBoard\u201d) has appointed Dr. Kenneth F. Buechler, Lead Independent Director, to non-executive Chairman, effective December 11, 2022. The separation of the Chairman and Chief Executive Officer roles is a key step toward strengthening the Company\u2019s governance practices and will facilitate the right balance between strong and consistent Company leadership and independent oversight by the Board. The Board also appointed Douglas Bryant to serve as President, in addition to Mr. Bryant\u2019s current role as Chief Executive Officer and a member of the Board.\n<\/p>\n

<\/a><\/p>\n

\n\u201cOn behalf of the Board, I want to thank Doug for his leadership as both Chairman and Chief Executive Officer and the strong execution of the transformational combination of Quidel Corporation and Ortho Clinical Diagnostics,\u201d said Dr. Buechler, Chairman of the Board. \u201cDoug has exceeded our expectations in integrating the Company while helping the commercial team maintain its near-term execution goals. As we look to the future, the Company has a significant opportunity to solidify its position as a leader in the IVD market and play a key role in meaningfully improving the global trajectory of human health.\u201d\n<\/p>\n

\n\u201cI have had the pleasure of working closely with Ken for many years and I am pleased that I will continue to benefit from his guidance and insights moving forward. He brings strategic oversight combined with a wealth of leadership and scientific industry expertise to our Board,\u201d said Mr. Bryant, President and Chief Executive Officer of QuidelOrtho. \u201cWith QuidelOrtho at the forefront of developing disease-specific biomarkers and tests, expanding centralized and point-of-care testing, changing the technological landscape with automation, and delivering strong performance across all business units, this is the right time for steadfast focus on executing on our strategic priorities and transforming the power of diagnostics into a healthier future for all.\u201d\n<\/p>\n

\nAdditionally, Robert J. Bujarski, Chief Operating Officer, and Michael S. Iskra, Chief Commercial Officer, have both been appointed to the newly created Executive Vice President roles, in addition to serving in their existing leadership roles. \u201cWith the exceptional leadership provided by Rob, Mike and our entire executive team, we have never been more confident in the strategic positioning of the Company to benefit from key market trends, the accelerating demand for diagnostic insights and the rapidly evolving IVD market,\u201d concluded Mr. Bryant. View QuidelOrtho\u2019s executive team here<\/a>.\n<\/p>\n

\nDr. Buechler has over 35 years of diagnostic industry expertise and several board roles. In November 2007, he was appointed to the board of directors of Quidel Corporation (\u201cQuidel\u201d) and prior to the combination with Ortho Clinical Diagnostics served as Quidel\u2019s Chairman since August 2015. Dr. Buechler was previously the co-founder of and held several scientific and research executive roles at Biosite Inc. from 1988 until its acquisition by Alere Inc. in 2007. Prior to co-founding Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated.\n<\/p>\n

\nAbout QuidelOrtho Corporation<\/b>\n<\/p>\n

\nQuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.\n<\/p>\n

\nRanked among the world\u2019s largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.\n<\/p>\n

\nOur Company\u2019s comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, QuidelOrtho is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit www.quidelortho.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking statements in this press release by words such as \u201cmay\u201d, \u201cwill\u201d, \u201cwould\u201d, \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201ccontinue\u201d, or similar words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, QuidelOrtho\u2019s future plans, objectives, strategies, expectations and intentions, and other statements that are not historical facts. Such statements are based on the beliefs and expectations of QuidelOrtho\u2019s management as of today and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth or implied in the forward-looking statements.\n<\/p>\n

\nThe following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies; the ability to retain key employees; and other economic, business, competitive, and\/or regulatory factors affecting the business of QuidelOrtho generally. Additional risks and factors are identified under \u201cRisk Factors\u201d in QuidelOrtho\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the \u201cCommission\u201d) on August 5, 2022, and subsequent reports filed with the Commission.\n<\/p>\n

\nYou should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. QuidelOrtho has no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
Bryan Brokmeier, CFA
\n
IR@Quidel.com<\/a>\n<\/p>\n

\nMedia Contact
\n
media@Quidel.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director; Assumes role as President SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (Nasdaq: QDEL) (\u201cQuidelOrtho\u201d or the \u201cCompany\u201d), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51886","6":"format-standard","7":"category-industry"},"yoast_head":"\nQuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director; Assumes role as President SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (Nasdaq: QDEL) (\u201cQuidelOrtho\u201d or the \u201cCompany\u201d), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T22:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles\",\"datePublished\":\"2022-12-12T22:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/\"},\"wordCount\":993,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005815\\\/en\\\/1662660\\\/21\\\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/\",\"name\":\"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005815\\\/en\\\/1662660\\\/21\\\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg\",\"datePublished\":\"2022-12-12T22:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005815\\\/en\\\/1662660\\\/21\\\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221212005815\\\/en\\\/1662660\\\/21\\\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/","og_locale":"en_US","og_type":"article","og_title":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend","og_description":"Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director; Assumes role as President SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (Nasdaq: QDEL) (\u201cQuidelOrtho\u201d or the \u201cCompany\u201d), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-12T22:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles","datePublished":"2022-12-12T22:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/"},"wordCount":993,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/","url":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/","name":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg","datePublished":"2022-12-12T22:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221212005815\/en\/1662660\/21\/QO_logo_hrz_VIOLET-1677px-1-768x92.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/quidelortho-announces-separation-of-chairman-and-chief-executive-officer-roles\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51886"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51886\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}